A randomized, double-blind, placebo-controlled, multicenter clinical trial of Yinxieping tablets in the treatment of mild to moderate psoriasis vulgaris
- Conditions
- Psoriasis vulgaris
- Registration Number
- ITMCTR2100005102
- Lead Sponsor
- Shaanxi Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria of Western medicine for guttate or plaque psoriasis and the diagnostic criteria for TCM syndromes of psoriasis;
2. Skin lesions involving <=10% BSA;
3. PASI score<=12;
4. Aged 18-65 years, gender is not limited;
5. Those who agree to participate in this study and sign the informed consent form.
1. Those with other active skin diseases that may affect the assessment of the condition;
2. Have systematically received treatment with investigational drugs, biological agents and immunosuppressive agents within 1 month;
3. Received topical corticosteroids, phototherapy and other treatments within 2 weeks;
4. In a state of severe and uncontrollable local or systemic acute or chronic infection;
5. Patients with severe systemic diseases; or patients whose clinical test indicators belong to one of the following conditions: increased alanine aminotransferase or aspartate aminotransferase > 1.5 times the upper limit of normal; increased creatinine > the upper limit of normal; any one of the main indicators of blood routine (white blood cell count, hemoglobin concentration, platelet count) < the lower limit of normal value or > > the upper limit of normal value; or other abnormal laboratory examinations in patients who are not suitable for participating in this trial;
6. Patients with a history of malignant tumors and patients with primary or secondary immunodeficiency and hypersensitivity;
7. Have undergone major surgery within 8 weeks or will require such surgery during the study;
8. Pregnant or lactating patients;
9. Those with a history of alcohol, drug or drug abuse;
10. Those with a history of serious mental illness or family history;
11. Participate in other clinical trials;
12. For other reasons, the researcher believes that it is not suitable to participate in this researcher.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method psoriasis area and severity index;
- Secondary Outcome Measures
Name Time Method onset time;body surface area;dermatology life quality index;recurrence rate;visual analogue scale;